Back to today’s briefing

Story perspectives

New Decoy Receptor Boosts CAR-T Cell Cancer Fighting Power

7/24/2025

50 7

Summary

Story summary

Engineered immune cells, such as CAR-T cells, face a significant hurdle: they frequently self-destruct due to the FAS-FAS ligand interaction. However, a groundbreaking study led by Dr. Christopher A. Klebanoff at Memorial Sloan Kettering Cancer Center introduces a decoy receptor that blocks this destructive signal, boosting the cells' power against tumors. This pivotal research is featured in Nature Cancer.

1 of 1

Story summary

Engineered immune cells, such as CAR-T cells, face a significant hurdle: they frequently self-destruct due to the FAS-FAS ligand interaction. However, a groundbreaking study led by Dr. Christopher A. Klebanoff at Memorial Sloan Kettering Cancer Center introduces a decoy receptor that blocks this destructive signal, boosting the cells' power against tumors. This pivotal research is featured in Nature Cancer.